Logo

Moderna's mRNA-1273 COVID-19 Vaccine Demonstrate Immune Responses in Older Adults

Share this

Moderna's mRNA-1273 COVID-19 Vaccine Demonstrate Immune Responses in Older Adults

Shots:

  • Moderna reported the publication of the second interim analysis of the open-label P-I study of mRNA-1273 in the NEJM. The study evaluated a 2dose vaccination schedule of mRNA-1273 given 28 days apart in 40 adults across two dose levels (25/100µg) in two age cohorts (56-70/ 71+) and reports results @Day 57 (1mos. following the second dose)
  • mRNA-1273 induced consistently high levels of pseudovirus neutralization Ab titers in all participants- elicited Th1-biased CD4 T cell responses across all age group- neutralizing Ab titers and T cell responses is consistent with reported in younger adults- both the doses were well tolerated
  • Results were consistent using 3 live virus assays. Additionally- the US government has agreed to purchase 100M doses of mRNA-1273- with an option to purchase an additional 400M dose

­ Ref: Moderna | Image: Moderna

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions